Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of MRX-8 in Healthy Volunteers
NCT04649541Phase 1Completed
- Sponsor
- MicuRx Pharmaceuticals
- Start
- Nov 2020
- Primary completion
- Dec 2021
- Modality
- Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MRX-8 in Gram-negative bacterial infection (6 arms), sponsored by MicuRx Pharmaceuticals. Primary endpoints: Adverse events, Clinical laboratory assessment and 4 more. Started Nov 2020; status: completed.
02
Drugs
MRX-8
03
Conditions
Gram-negative bacterial infection
Beyond the preview
Go deeper on NCT04649541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04649541.